PharmiWeb Today Story
Upon completion, this acquisition will expand Lilly's growing U.S. capacity to produce the latest life-changing medicines
INDIANAPOLIS and LINCOLNSHIRE, Ill., April 22, 2024 – Eli Lilly and Company (NYSE: LLY) and Nexus Pharmaceuticals, LLC today announced a definitive agreement for Lilly to acquire a manufacturing facility from Nexus, a leading sterile manufacturer in the pharmaceutical industry.
The acquisition of this FDA-approved facility in Pleasant Prairie, Wisconsin will further expand Lilly's global parenteral (injectable) product manufacturing network and support increased demand for the company's medicines. Lilly estimates that production at this facility could begin at the end of 2025.
“The acquisition of this state-of-the-art facility underscores our unwavering commitment to growth and innovation, and we look forward to welcoming talented new Nexus colleagues to Lilly from the Pleasant Prairie facility,” said Edgardo Hernandez, executive vice president and president, Lilly manufacturing. “We are investing boldly to serve our patients, to meet product demand and to build capabilities for our robust pipeline of the future.”
Usman Ahmed, president and chief executive officer of Nexus, added: “We are excited Lilly is continuing our family’s mission of providing lifesaving medications to those who need them most. This milestone is a testament to the dedication of our Nexus employees in building a best-in-class injectable manufacturing facility. The combination of our teams and infrastructure with Lilly’s global platform will benefit…
Read More...Articles
What Does a Clinical SAS Programmer Do?
16-Apr-2024
The Evolution of Clinical Data Management
10-Apr-2024
9 Clinical Data Management Career Paths
08-Apr-2024
Featured Events
-
HFpEF Drug Discovery & Development Summit 2022
25-Jan-2022 - 27-Jan-2022 -
UK Clinical Research: A Professional Awareness Upd…
26-Jan-2022 - 27-Jan-2022 -
Bioprocessing and the future of food
06-Jul-2022 - 07-Jul-2022 -
PM Society: Measuring Patient Engagement: Opening…
12-Oct-2022 - 12-Oct-2022 -
How to impact, influence & inspire
07-Feb-2023 - 21-Feb-2023 -
Reuters Events: Pharma USA 2023
28-Mar-2023 - 29-Mar-2023
News
-
Adastra Holdings Reports FY2023 Results; Marking T…
24-Apr-2024 -
Medicure Receives US FDA Fast Track Designation fo…
23-Apr-2024 -
Laxxon Medical to Participate in the World Orphan…
23-Apr-2024 -
Evotec SE appoints Dr Christian Wojczewski as Chie…
23-Apr-2024 -
Evotec SE appoints Dr Christian Wojczewski as Chie…
23-Apr-2024 -
Evotec SE appoints Dr Christian Wojczewski as Chie…
23-Apr-2024